Trial Profile
A Study to Evaluate the Efficacy and Safety of MK-5172 in Combination with Peginterferon alfa 2b and Ribavirin in Cirrhotic and Non-cirrhotic Patients with Hepatitis C Virus (HCV) genotype 1 Infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Grazoprevir (Primary) ; Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- 19 Dec 2015 New trial record